Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369719 | 0.92 | L3MBTL1 (0.41) | L3MBTL1POLBTSHRLMNANPC1 | |
| SCHEMBL2773813 | 0.84 | KDM4E (0.41) | L3MBTL1POLBTSHRLMNANPC1 | |
| SCHEMBL17158071 | 0.83 | PKM (0.38) | L3MBTL1CCR2PTGS2CA1CA2 | |
| SCHEMBL24651345 | 0.83 | L3MBTL1 (0.42) | L3MBTL1TSHRLMNACCR2SLC9A1 | |
| SCHEMBL19613829 | 0.82 | POLB (0.37) | L3MBTL1POLBTSHRLMNANPC1 | |
| SCHEMBL25257871 | 0.81 | L3MBTL1 (0.45) | L3MBTL1POLBTSHRLMNANPC1 | |
| SCHEMBL21633472 | 0.79 | CCR2 (0.37) | L3MBTL1CCR2PTGS2CA1CA2 | |
| SCHEMBL22637253 | 0.78 | CA1 (0.39) | L3MBTL1CCR2CA1CA2CA9 | |
| SCHEMBL17071846 | 0.78 | CCR2 (0.41) | CCR2PTGS2CA1CA2CA9 | |
| SCHEMBL4532586 | 0.78 | L3MBTL1 (0.38) | L3MBTL1CCR2SLC9A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033342-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015022073-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2015-02-19 | — | — | WO | disclosed |
| US-8101612-B2 | N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes | AMGEN INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2077998-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2077998-A1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030466-A1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | L3MBTL1 4431/4885POLB 2547/4885TSHR 2088/4885 |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | AADAC, PRRC2C, PRRC2A | L3MBTL1 4626/4885POLB 1083/4885TSHR 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.